Additionally, we examined treatment response according to RECIST 1.1 criteria, which standardizes tumor response assessment in solid tumors, and conducted subgroup analyses by stage, PD-L1 tumor proportion score, treatment type, and molecular markers to provide a comprehensive understanding of these biomarkers’ utility in real-world clinical practice. This evidence concerns the gene CD274 and neoplasm.